BB Biotech swings to H1 FY26 profit of CHF 430 million; Q2 profit totals CHF 451 million

• BB Biotech swung to a profit of CHF 430 million in the first half, reversing a CHF 341 million loss a year earlier.
• Second-quarter net profit rose to CHF 451 million from a CHF 100 million loss in the prior-year period.
• Results primarily reflected share-price moves in portfolio holdings, consistent with its investment-company model.
• Dividend policy was revised effective fiscal 2026, targeting a 3%-5% annual dividend yield instead of a fixed payout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BB Biotech AG published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.